Hologic, a women’s health expert, has acquired a Finnish-French developer of innovative molecular diagnostic tests and instrumentation, Mobidiag, for six-hundred and sixty-eight million euros. The deal includes a cash payment of roughly six hundred million euros for Mobidiag’s equity and net debt of roughly sixty-eight million euros.
Mobidiag’s CEO, Tuomas Tenkanen, stated: “We are very excited to join Hologic’s diagnostic business. Under the Hologic umbrella, our business will continue to be committed to its existing customer base in Europe, including our home markets of Finland, France, Sweden and UK, however, Hologic’s commercial expertise, scale and investment strength will accelerate the broader market adoption of our products. In addition, Hologic’s established U.S. regulatory and market development capabilities will rapidly facilitate the introduction of our products and maximise their potential in the United States.”
“Hologic acquires Mobidiag.“
Group president, international, Hologic, Jan Verstreken, stated: “Acquiring Mobidiag will further strengthen our international diagnostics businesses by providing a European R&D and manufacturing centre of excellence, enabling us to expand into the large, fast-growing acute care adjacency with a near-patient testing solution that offers ease of use, multiplex capability and rapid turnaround time. We believe that Mobidiag has a highly complementary product offering and has developed a differentiated platform that addresses many of the historical challenges of multiplexed point-of-care molecular testing.”